Clinical application of blood matching with hemolytic test in vitro for transfusion treatment of crisis puerpera with acute hemolytic anemia.
10.7534/j.issn.1009-2137.2014.04.039
- Author:
Min YUAN
1
;
Cong-Hai TANG
2
;
Wei-Wei GAN
1
;
A-Yang WU
1
;
Hui-Cong YANG
1
;
Tian-Xin ZHANG
1
;
Yan Xue HUANG
1
;
Lu-Zhen QIU
1
;
Hong-Pu CHEN
1
;
Feng-Li LIN
1
Author Information
1. Department of Transfusion Blood, Zhangzhou Municipal Hospital Affiliated to Fujian Medical University, Zhangzhou 363000, Fujian Province, China.
2. Department of Transfusion Blood, Zhangzhou Municipal Hospital Affiliated to Fujian Medical University, Zhangzhou 363000, Fujian Province, China. E-mail: 23095721@qq.com.
- Publication Type:Case Reports
- MeSH:
Anemia, Hemolytic;
therapy;
Blood Grouping and Crossmatching;
methods;
Erythrocyte Transfusion;
methods;
Female;
Humans;
Puerperal Disorders;
therapy;
Young Adult
- From:
Journal of Experimental Hematology
2014;22(4):1094-1098
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to establish the matching method of hemolytic test in vitro, and to guide the transfusion treatment for puerpera with acute hemolytic disease. The donor's erythrocytes were sensibilized by all the antibodies in plasma of patient in vitro and were added with complement, after incubation for 6.5 hours at 38 °C, the hemolysis or no hemolysis were observed. It is safe to transfuse if the hemolysis did not occur. The results showed that when the matching difficulty happened to puerpera with acute hemolytic disease, the compatible donor could be screened by hemolytic test in vitro. There were no untoward effects after transfusion of 6 U leukocyte-depleted erythrocyte suspension. The all hemoglobin, total bilirubins, indirect bilirubin, reticulocyte, D-dimex and so on were rapidly improved in patient after transfusion , showing obvious clinical efficacy of treatment. It is concluded that when the matching results can not judge accurately compatible or incompatible through the routine method of cross matching, the agglutinated and no-hemolytic erythrocytes can be screened by hemolytic test in vitro and can be transfused with good efficacy; the hemoglobin level can be promoted rapidly, and no untoward effects occur.
